Dasatinib-induced chylothorax: report of a case and review of the literature
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-00932-3
Abstract: Dasatinib is a tyrosine kinase inhibitor for the treatment of BCR-ABL-positive chronic myeloid leukaemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL). Although fluid retention is a common adverse event associated with dasatinib, chylothorax is… read more here.
Keywords: dasatinib induced; chylothorax; dasatinib; case ... See more keywords